- Home
- SM vs APGE Comparison
SM vs APGE Comparison
Compare SM & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SM
- APGE
- Stock Information
- Founded
- SM 1908
- APGE 2022
- Country
- SM United States
- APGE United States
- Employees
- SM N/A
- APGE N/A
- Industry
- SM Oil & Gas Production
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SM Energy
- APGE Health Care
- Exchange
- SM Nasdaq
- APGE Nasdaq
- Market Cap
- SM 3.0B
- APGE 2.6B
- IPO Year
- SM 1992
- APGE 2023
- Fundamental
- Price
- SM $28.52
- APGE $38.14
- Analyst Decision
- SM Hold
- APGE Strong Buy
- Analyst Count
- SM 11
- APGE 4
- Target Price
- SM $42.44
- APGE $97.50
- AVG Volume (30 Days)
- SM 2.5M
- APGE 1.4M
- Earning Date
- SM 08-06-2025
- APGE 08-11-2025
- Dividend Yield
- SM 2.82%
- APGE N/A
- EPS Growth
- SM 11.97
- APGE N/A
- EPS
- SM 7.14
- APGE N/A
- Revenue
- SM $2,847,233,000.00
- APGE N/A
- Revenue This Year
- SM $30.95
- APGE N/A
- Revenue Next Year
- SM $1.16
- APGE $743.14
- P/E Ratio
- SM $4.00
- APGE N/A
- Revenue Growth
- SM 24.88
- APGE N/A
- 52 Week Low
- SM $19.67
- APGE $26.20
- 52 Week High
- SM $48.49
- APGE $63.50
- Technical
- Relative Strength Index (RSI)
- SM 63.96
- APGE 43.45
- Support Level
- SM $27.00
- APGE $36.40
- Resistance Level
- SM $28.12
- APGE $39.33
- Average True Range (ATR)
- SM 1.24
- APGE 3.04
- MACD
- SM 0.23
- APGE -0.83
- Stochastic Oscillator
- SM 88.44
- APGE 20.25
About SM SM Energy Company
SM Energy Co is an independent energy company engaged in the acquisition, exploration, development, and production of oil, gas, and NGLs in Texas and Utah. Its portfolio is comprised of assets in the Midland Basin of West Texas, the Maverick Basin of South Texas, and the Uinta Basin of northeastern Utah.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.